NECTIN-4 Offers Attractive Target in Urothelial Cancer and Beyond
As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.
Source: onclive.com
First Approved News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from First Approved. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In First Approved Today - Breaking & Trending Today
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer
Source: eagletribune.com
BioBlast w/e 23 Oct 23
Celltrion announced that the FDA has approved its subcutaneous formulation of Zymfentra® (infliximab -dyyb), biosimilar to Janssen’s Remicade®, as…
Source: lexology.com
FTSE 100 Poised to Fall After Mixed Asia Session, U.S. Losses - Stock market news
FTSE 100 Poised to Fall After Mixed Asia, US Losses 0630 GMT - The FTSE 100 looks set to open 28 points lower at 7760 after mixed trading in Asia and a lower close on Wall Street. Markets in mainland China and South Korea fall and Australian shares... | 02:53am
Source: marketscreener.com
Unituxin Patent, Sales & Clinical Trials Outlook, 2028: 10 Clinical Studies, Role in Cancer Therapy, Structure & Pharmacokinetics Properties
/PRNewswire/ -- The "Unituxin Patent, Sales & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Global Unituxin market...
Source: prnewswire.com